(Q44165254)

English

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease

scientific article published in September 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert A Hauser

1

object named as

Robert A Hauser

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Nicholas H G Holford

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

1 September 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Movement Disorders

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

961-968

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

The effect of deprenyl and levodopa on the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10226

21 January 2018

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10226

21 January 2018

A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10226

21 January 2018

Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10226

21 January 2018

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10226

21 January 2018

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FMDS.10226

21 January 2018

Identifiers

10.1002/MDS.10226

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44165254&oldid=2107337005"